Fig. 3

a: Computed Tomography (CT) scan in February after treatment with a PD-L1 inhibitor. b: CT scan showing smaller lesions in April 2018 after treatment with Sorafenib
a: Computed Tomography (CT) scan in February after treatment with a PD-L1 inhibitor. b: CT scan showing smaller lesions in April 2018 after treatment with Sorafenib